TW202302086A - 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法 - Google Patents

辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法 Download PDF

Info

Publication number
TW202302086A
TW202302086A TW111106378A TW111106378A TW202302086A TW 202302086 A TW202302086 A TW 202302086A TW 111106378 A TW111106378 A TW 111106378A TW 111106378 A TW111106378 A TW 111106378A TW 202302086 A TW202302086 A TW 202302086A
Authority
TW
Taiwan
Prior art keywords
beads
ctn
pharmaceutical formulation
range
release
Prior art date
Application number
TW111106378A
Other languages
English (en)
Chinese (zh)
Inventor
席德 阿斯法 馬丁
普雷文 庫馬爾 米迪多迪
薛伊利 米若特拉
蘇珊 伊莉莎白 蕭艾
沙琳 古塔
鈴木海
長谷川真裕
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW202302086A publication Critical patent/TW202302086A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
TW111106378A 2021-02-23 2022-02-22 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法 TW202302086A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163152826P 2021-02-23 2021-02-23
US63/152,826 2021-02-23
US202163241839P 2021-09-08 2021-09-08
US63/241,839 2021-09-08

Publications (1)

Publication Number Publication Date
TW202302086A true TW202302086A (zh) 2023-01-16

Family

ID=80735736

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111106378A TW202302086A (zh) 2021-02-23 2022-02-22 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法

Country Status (11)

Country Link
US (6) US11564885B2 (enExample)
EP (1) EP4297734A1 (enExample)
JP (2) JP7787190B2 (enExample)
KR (1) KR20230152046A (enExample)
AU (1) AU2022227367A1 (enExample)
BR (1) BR112023015272A2 (enExample)
CA (1) CA3205786A1 (enExample)
IL (1) IL303767A (enExample)
MX (1) MX2023009833A (enExample)
TW (1) TW202302086A (enExample)
WO (1) WO2022181625A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023015272A2 (pt) * 2021-02-23 2023-11-07 Otsuka Pharma Co Ltd Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
KR20250053128A (ko) * 2022-08-24 2025-04-21 오츠카 세이야쿠 가부시키가이샤 센타나파딘을 포함하는 제약 조성물
US20250375418A1 (en) * 2022-09-02 2025-12-11 Otsuka Pharmaceutical Co., Ltd. 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder
WO2025183181A1 (en) 2024-02-28 2025-09-04 Otsuka Pharmaceutical Co., Ltd. Use of centanafadine in treatment of adhd symptoms
US12502358B1 (en) 2024-08-13 2025-12-23 Innovate Therapeutics Llc Centanafadine multiphasic controlled-release pharmaceutical formulation
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2006133349A2 (en) 2005-06-08 2006-12-14 Alpharma, Inc. Orally disintegrable sleep aid formulations
EP1915146A4 (en) * 2005-07-27 2010-06-02 Dov Pharmaceutical Inc NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES
ES2529455T3 (es) * 2006-05-12 2015-02-20 Shire Llc Sistema de administración de fármacos por dosis controladas
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US20140206740A1 (en) * 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN107335057A (zh) 2012-07-27 2017-11-10 韦尔斯利医药有限公司 用于缓解尿频的药物制剂及其使用方法
CN106029637A (zh) 2013-12-09 2016-10-12 纽罗万斯公司 新的组合物
EP3069715A1 (en) * 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
US20180008575A1 (en) 2016-07-11 2018-01-11 Neurovance, Inc. Methods of treating binge eating disorder
BR112023015272A2 (pt) * 2021-02-23 2023-11-07 Otsuka Pharma Co Ltd Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas

Also Published As

Publication number Publication date
AU2022227367A1 (en) 2023-08-03
US20250041225A1 (en) 2025-02-06
US11564885B2 (en) 2023-01-31
US20230338293A1 (en) 2023-10-26
JP7787190B2 (ja) 2025-12-16
MX2023009833A (es) 2023-09-04
US20240165030A1 (en) 2024-05-23
JP2024506595A (ja) 2024-02-14
EP4297734A1 (en) 2024-01-03
US11980690B2 (en) 2024-05-14
US12156941B2 (en) 2024-12-03
AU2022227367A9 (en) 2024-10-17
US11759426B2 (en) 2023-09-19
IL303767A (en) 2023-08-01
JP2025183214A (ja) 2025-12-16
US20250319030A1 (en) 2025-10-16
US20220265557A1 (en) 2022-08-25
BR112023015272A2 (pt) 2023-11-07
CA3205786A1 (en) 2022-09-01
WO2022181625A1 (en) 2022-09-01
US12370144B2 (en) 2025-07-29
US20230104529A1 (en) 2023-04-06
KR20230152046A (ko) 2023-11-02

Similar Documents

Publication Publication Date Title
TW202302086A (zh) 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法
CN102458117B (zh) 含有非阿片样和阿片样止痛药的组合的口腔崩解片组合物
AU2007211101B2 (en) Drug delivery systems comprising weakly basic drugs and organic acids
CN101410094B (zh) 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
TWI747810B (zh) 特別用於治療注意力缺失症之方法及組成物
CN102869349A (zh) 耐酒精的肠溶药物组合物
CN112789042A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
CN104394854A (zh) 具有增强活性和降低毒性的包括硝呋替莫的硝基呋喃的新型制剂
JP2025529250A (ja) 大うつ病性障害の治療のための１－（ナフタレン－２－イル）－３－アザビシクロ［３．１．０］ヘキサン
EA052298B1 (ru) Фармацевтические составы центанафадина и способы их получения и применения
HK40098701A (zh) 森塔纳法啶药物制剂及其制备和使用方法
CN116710078A (zh) 森塔纳法啶药物制剂及其制备和使用方法
AU2013204400B2 (en) Drug delivery systems comprising weakly basic drugs and organic acids
HK40118462A (zh) 用於治疗重度抑郁症的1-(萘-2-基)-3-氮杂双环[3.1.0]己烷
AU2013204408B2 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
WO2007120136A1 (en) Lercanidipine ph dependent pulsatile release compositions